Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
HOUSTON, March 15, 2018 -- PLx Pharma Inc. (NASDAQ:PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec™ 325 mg and Aspertec™ 81 mg (referred to together as “Aspertec”™), today announced that the Company will release its 2017 fourth quarter and full year financial results on Friday, March 23, 2018, before the U.S. financial markets open.
Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will host a conference call to discuss the results as follows:
| Date | Friday, March 23, 2018 | |||
| Time | 8:30 a.m. EDT | |||
| Toll free (U.S.) | (866) 394-2901 | |||
| International | (616) 548-5567 | |||
| Webcast (live and replay) | www.plxpharma.com under the ‘Investor Relations’ section. |
A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International). The conference ID for the replay is 8198566. The archived webcast will be available for 30 days via the aforementioned URL.
About Aspertec
Aspertec 325 mg is an FDA-approved aspirin product being developed to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy as compared to enteric-coated aspirin, while also reducing the adverse gastric events common in an acute setting. PLx is focused on completing manufacturing scale-up and label finalization for Aspertec 325 mg aspirin dosage form and preparing an sNDA for Aspertec 81 mg maintenance dose form.
About PLx Pharma Inc.
PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide effective and safe aspirin products. The PLxGuard delivery system works by targeting delivery of active pharmaceutical ingredients (API) to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce acute GI side effects—including erosions, ulcers and bleeding—associated with aspirin and ibuprofen, and potentially other drugs.
To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.
Contact
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: [email protected]
